BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Girardin M, Manz M, Manser C, Biedermann L, Wanner R, Frei P, Safroneeva E, Mottet C, Rogler G, Schoepfer AM. First-line therapies in inflammatory bowel disease. Digestion. 2012;86 Suppl 1:6-10. [PMID: 23051720 DOI: 10.1159/000341951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Lee YM, Kang B, Lee Y, Kim MJ, Choe YH. Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. Journal of Pediatric Gastroenterology & Nutrition 2015;60:737-43. [DOI: 10.1097/mpg.0000000000000711] [Cited by in Crossref: 34] [Cited by in F6Publishing: 14] [Article Influence: 4.9] [Reference Citation Analysis]
2 Quaglio AE, Castilho AC, Di Stasi LC. Experimental evidence of heparanase, Hsp70 and NF-κB gene expression on the response of anti-inflammatory drugs in TNBS-induced colonic inflammation. Life Sci 2015;141:179-87. [PMID: 26434698 DOI: 10.1016/j.lfs.2015.09.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.9] [Reference Citation Analysis]
3 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Orsi PR, Seito LN, Di Stasi LC. Hymenaea stigonocarpa Mart. ex Hayne: A tropical medicinal plant with intestinal anti-inflammatory activity in TNBS model of intestinal inflammation in rats. J Ethnopharmacol. 2014;151:380-385. [PMID: 24211392 DOI: 10.1016/j.jep.2013.10.056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
5 D'Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan BG; Laquinimod for Crohn's Disease Investigators. A phase II study of laquinimod in Crohn's disease. Gut 2015;64:1227-35. [PMID: 25281416 DOI: 10.1136/gutjnl-2014-307118] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 7.6] [Reference Citation Analysis]
6 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
7 Breitrück A, Sparmann G, Mitzner S, Kerkhoff C. Establishment of a novel extracorporeal bowel model to study luminal approaches to treat inflammatory bowel disease. Dis Model Mech 2013;6:1487-93. [PMID: 24046362 DOI: 10.1242/dmm.011734] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
8 Assimakopoulos SF, Stamouli V, Dimitropoulou D, Spiliopoulou A, Panos G, Anastassiou ED, Marangos M, Spiliopoulou I. Toxoplasma gondii meningoencephalitis without cerebral MRI findings in a patient with ulcerative colitis under immunosuppressive treatment. Infection 2015;43:589-93. [PMID: 25623638 DOI: 10.1007/s15010-015-0730-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
9 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
10 Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li HS, Yang CM. Mechanisms underlying therapeutic effects of DPP-4 inhibitor against ulcerative colitis in mice. Shijie Huaren Xiaohua Zazhi 2013; 21(29): 3102-3106 [DOI: 10.11569/wcjd.v21.i29.3102] [Reference Citation Analysis]
12 Neunert C, Farah R, Yacobovich J, Neufeld E. Refractory autoimmune disease: an overview of when first-line therapy is not enough. Seminars in Hematology 2016;53:S35-8. [DOI: 10.1053/j.seminhematol.2016.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Abdallah T, Abdallah M, Saifan C, El Sayegh D, Chalhoub M, Sasso L. Hemidiaphragm paresis and granulomatous pneumonitis associated with adalimumab: a case report. Heart Lung 2014;43:84-6. [PMID: 24246727 DOI: 10.1016/j.hrtlng.2013.10.010] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
14 Matsuo S, Yang WL, Aziz M, Kameoka S, Wang P. Fatty acid synthase inhibitor C75 ameliorates experimental colitis. Mol Med 2014;20:1-9. [PMID: 24306512 DOI: 10.2119/molmed.2013.00113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
15 Lapumnuaypol K, Kanjanahattakij N, Pisarcik D, Thongprayoon C, Wijarnpreecha K, Cheungpasitporn W. Effects of inflammatory bowel disease treatment on the risk of nonalcoholic fatty liver disease: a meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:854-860. [PMID: 29697458 DOI: 10.1097/meg.0000000000001144] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
16 Tigno-Aranjuez JT, Benderitter P, Rombouts F, Deroose F, Bai X, Mattioli B, Cominelli F, Pizarro TT, Hoflack J, Abbott DW. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem 2014;289:29651-64. [PMID: 25213858 DOI: 10.1074/jbc.M114.591388] [Cited by in Crossref: 65] [Cited by in F6Publishing: 35] [Article Influence: 8.1] [Reference Citation Analysis]
17 Wu B, Tong J, Ran Z. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2020;26:24-32. [PMID: 30980713 DOI: 10.1093/ibd/izz068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
18 T Virtanen A, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019;33:15-32. [PMID: 30701418 DOI: 10.1007/s40259-019-00333-w] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 25.3] [Reference Citation Analysis]
19 Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 2014;121:358-64. [PMID: 24011995 DOI: 10.1016/j.ophtha.2013.07.019] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
20 Londono R, Badylak SF. Biomaterials from Decellularized Tissues. In: Neves NM, Reis RL, editors. Biomaterials from Nature for Advanced Devices and Therapies. Hoboken: John Wiley & Sons, Inc.; 2016. pp. 190-210. [DOI: 10.1002/9781119126218.ch12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ladizinski B, Lee KC. Infliximab-induced urticaria. J Emerg Med 2014;46:691-2. [PMID: 24484626 DOI: 10.1016/j.jemermed.2013.10.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Yazısız V. Similarities and differences between Behçet's disease and Crohn's disease. World J Gastrointest Pathophysiol 2014; 5(3): 228-238 [PMID: 25133025 DOI: 10.4291/wjgp.v5.i3.228] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
23 Perrone G, Brunelli R, Marcoccia E, Zannini I, Candelieri M, Gozzer M, Stefanutti C. Therapeutic Apheresis in Pregnancy: Three Differential Indications With Positive Maternal and Fetal Outcome: Therapeutic Apheresis in Pregnancy. Ther Apher Dial 2016;20:677-85. [DOI: 10.1111/1744-9987.12422] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 Savarino JR, Kaplan JL, Winter HS, Moran CJ, Israel EJ. Improving Clinical Remission Rates in Pediatric Inflammatory Bowel Disease with Previsit Planning. BMJ Qual Improv Rep 2016;5:u211063. [PMID: 27559471 DOI: 10.1136/bmjquality.u211063.w4361] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]